Pathologic Dilatation (Ectasia)

05/01/2011 - "Corneal collagen CXL appeared effective in halting the progression of corneal ectasia. "
07/01/2014 - "New studies also demonstrate the use of collagen cross-linking in postrefractive surgery ectasia. "
05/01/2013 - "This study shows that corneal collagen cross-linking can stabilize progressive corneal ectasia, both primary and secondary, with no induced iatrogenic effects."
10/01/2015 - "To evaluate 6-year results of standardized epithelium-off corneal collagen cross-linking (CXL) for treatment of progressive corneal ectasia. "
10/01/2015 - "Corneal Collagen Cross-linking for the Treatment of Progressive Corneal Ectasia: 6-Year Prospective Outcome in a French Population."

09/01/2007 - "According to the angiographic definition used in the Coronary Artery Surgery Study, a vessel is considered to be ectasic when its diameter is > or = 1.5 times that of the adjacent normal segment in segmental ectasia. "
02/01/2005 - "According to the angiographic definition used in the Coronary Artery Surgery Study, a vessel is considered to be ectasic when its diameter is > or =1.5 times that of the adjacent normal segment in segmental ectasia. "
08/01/2015 - "Ectasia of the capillaries, though subject to strictly individual variables, can be considered perfectly normal and it is compatible with the normal biology and physiology of vessel microcirculation."
09/01/2014 - "Patients in elderly group were found to have significantly higher proportion of female (30.1% vs. 10.1%, P < 0.001), three-vessel disease (60.5% vs. 45.2%, P = 0.003) and localized ectasia (55.0% vs. 40.2%, P = 0.003). "
01/01/2014 - "Coronary artery ectasia (CAE) is commonly defined as local or generalized dilatation of a coronary vessel up to 1.5 times the diameter of an adjacent vessel. "

11/01/2012 - "Cross-linking with riboflavin and ultraviolet A light is a promising, minimally invasive treatment for corneal ectasia. "
01/01/2012 - "Combination of riboflavin/UVA cross-linking (CXL) and excimer laser ablation is a promising therapy for treating corneal ectasia. "
12/01/2007 - "A 27-year-old man presented with corneal ectasia in his left eye 4 years after myopic laser in situ keratomileusis (LASIK) and was treated with riboflavin-ultraviolet-A (crosslinking). "
02/01/2011 - "Riboflavin UV-A-induced corneal cross-linking seems to be a promising surgical option in the management of unstable corneal ectasia exacerbated by RK, particularly in eyes with preexisting keratoconus. "
10/01/2015 - "Eyes with an ectasia risk score of 2 or higher were treated with standard LASIK (90 μm flap) for myopia correction, after which a rapid corneal crosslinking was performed in the interface (riboflavin 0.5% for 2 minutes, 9 mW/cm(2) for 5 minutes) (Group 1). "

03/23/2004 - "MMP-9 or MMP-12 deficiency conferred significant protection against transmedial elastin degradation and ectasia in the atherosclerotic media. "
06/30/1999 - "at 50 mg/kg) had no effect on the extent of aortic atherosclerosis (36 +/- 4% versus 30 +/- 2% in controls), but both aortic medial elastin destruction and ectasia grade were significantly reduced (38% and 36%, respectively, p < 0.05). "
07/16/1982 - "These findings point to a change in the structure or metabolism of elastin in the aortic wall in the Marfan syndrome and at least in some other patients with annulo-aortic ectasia."
11/15/1985 - "Aortic samples from patients with annulo-aortic ectasia (aneurysm of the ascending aorta), including one with classical Marfan syndrome, contained less elastin (CNBr-insoluble material) than did the age-matched controls. "
01/01/2007 - "The elastic lamellae undergo fragmentation and thinning, leading to ectasia and a gradual transfer of mechanical load to collagen, which is 100-1000 times stiffer than elastin. "

05/01/1999 - "Corneal ectasia after trabeculectomy with mitomycin C application."
01/01/2006 - "Adjunctive utilization of intraoperative low-dose 0.02% mitomycin C for the management of chronic uveitic glaucoma patients who are under concomitant systemic immunosuppressive regimen may enhance the risk of subacute postoperative sclerolimbal ectasia. "
01/01/2006 - "A case of early-onset sclerolimbal ectasia following low-dose topical mitomycin C application during uveitic glaucoma surgery is reported. "

04/15/1989 - "[Estrogen therapy in digestive hemorrhage caused by diffuse vascular ectasia of the gastric antrum]."
12/01/2005 - "Urgent aortic valve replacement (AVR) was performed after preoperative hormonal (estrogen-progesterone) therapy, that might be effective for bleeding from vascular ectasia. "

07/01/1991 - "In 51 cases the orchiectomy was combined with transurethral resection of the prostate (TURP); 37 patients had pathological levels of serum creatinine and 17 had pathological dilatation of the upper urinary tract, 6 of whom required a nephrostomy catheter. "
02/01/2009 - "Surgical POP repair resolved the prolapse all patients and cured the ureterohydronephrosis in 7, with moderate ectasia of the upper urinary tract persisting in 2. The renal function at diagnosis was normal in 12 of 13 patients with hydronephrosis (mean 113 +/- 15 micromol/L); 1 patient had a high serum creatinine concentration (220 micromol/L). "

05/01/1978 - "3) Thiazides are effective in normocalciuric as well as hypercalciuric patients and in most patients with tubular ectasia (medullary sponge kidney). "

01/01/2011 - "Following Asacol discontinuation, his chest pain resolved, troponins were trending towards normal, left ventricular systolic function normalized, and coronary ectasia improved within 24 hours suggesting an Asacol-associated severe drug reaction. "

05/01/2014 - "Placement of a titanium plate appears to be an effective method of treatment of cerebellar ptosis and dural ectasia after PFD for Chiari malformation."
05/01/2014 - "We describe our use of a perforated titanium plate to perform a partial posterior fossa cranioplasty in the treatment of cerebellar ptosis and dural ectasia after posterior fossa decompression (PFD). "

03/01/2003 - "Intracorneal ring segments implantation improved uncorrected visual acuity and best spectacle-corrected visual acuity in patients with post-LASIK ectasia. "
05/01/2008 - "The Ectasia Risk Score System is a valid and effective method for detecting eyes at risk for ectasia after LASIK and represents a significant improvement over previously utilized screening strategies."
01/01/2008 - "A quantitative method can be used to identify eyes at risk for developing ectasia after LASIK that, if validated, represents a significant improvement over current screening strategies."
09/01/2002 - "When used in combination with videokeratography, the Orbscan II topography system may be helpful in identifying patients who are potentially at high risk for developing ectasia after LASIK."
01/01/2002 - "Implantation of INTACS in eyes with corneal ectasia after LASIK resulted in good refractive outcome, absence of complications, and improvement in visual acuity."

05/01/2015 - "The current available therapies do not modify the underlying pathogenesis of the disease, and none of the available approaches but corneal transplant hinder the ongoing ectasia. "
08/01/2014 - "The progressive thinning and ectasia of the recipient bed can also result in internal graft-host dehiscence leading to chronic oedema. "
06/01/2014 - "Corneal transplants of 20 years or more show a higher rate of refits due to ectasia recurrence. "
03/01/2014 - "Novel approach for the treatment of corneal ectasia in a graft."
07/01/2013 - "Morphology of graft-host junction in cases with postkeratoplasty corneal ectasia."

02/01/2014 - "Efficacy of argon plasma coagulation in the treatment of radiation-induced hemorrhagic gastroduodenal vascular ectasia."
06/01/2014 - "Long-term treatment outcome of patients with gastric vascular ectasia treated with argon plasma coagulation."
05/14/2013 - "Thirty-eight patients with hemorrhagic gastric vascular ectasia (VE) were treated by endoscopic cauterization: 13 by heater probe coagulationand 25 by argon plasma coagulation. "
04/01/2009 - "Efficacy of argon plasma coagulation in gastric vascular ectasia in patients with liver cirrhosis."
09/01/2008 - "The beneficial effects of argon plasma coagulation in the management of different types of gastric vascular ectasia lesions in patients admitted for GI hemorrhage."

03/01/2007 - "Penetrating keratoplasty versus intrastromal corneal ring segments to correct bilateral corneal ectasia: preliminary study."
10/01/2012 - "PROSE treatment is an alternative to penetrating keratoplasty for patients with corneal ectasia who are contact lens intolerant."
02/01/2011 - "TILK can be successfully performed for post-penetrating keratoplasty corneal ectasia with peripheral corneal thinning."
01/01/2011 - "The management of corneal ectasia is evolving, with intrastromal corneal ring segments playing an important role in delaying or eliminating the need for penetrating keratoplasty. "
07/01/2007 - "These new forms of surgery are viable alternatives to conventional penetrating keratoplasty and bring added safety profiles for long-term visual rehabilitation and restoration of tectonic integrity in central and peripheral forms of corneal ectasia."

01/01/2011 - "Increasing aortic ectasia necessitated resection of the ascending aorta and implantation of a Vascutek 30 mm prosthesis. "
10/01/2000 - "Clinical introduction of a novel prosthesis for valve-preserving aortic root reconstruction for annuloaortic ectasia."
11/01/1979 - "Two patients had infected aortic valve prostheses, three patients had acute aortic dissection and three had annuloaortic ectasia. "
01/01/2010 - "The Boston Ocular Surface Prosthesis significantly improved VA and visual functioning in patients with corneal ectasia, irregular astigmatism, and ocular surface disease who had failed conventional therapies."
12/01/2009 - "Assuming that benefits persist for an average of 5 years, the lifetime gain was 0.48 QALYs; the average cost-effectiveness of the prosthesis was $24,900 per QALY (95% confidence interval $19,100 to $29,600), and the average benefit-cost ratio was 4.0 to 1. In patients with the lowest baseline scores (average VFQ score 38.6), results were even more favorable: cost-effectiveness $17,100 per QALY and benefit-cost ratio 5.6 to 1. The Boston Ocular Surface Prosthesis is cost-effective and cost beneficial in patients with severely compromised visual function attributable to ectasia, irregular astigmatism, or ocular surface disease."